1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Critical Limb Ischemia Treatment Market
2.3. Global Critical Limb Ischemia Treatment Market, By Treatment, 2025 (US$ Million)
2.4. Global Critical Limb Ischemia Treatment Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025

3. Critical Limb Ischemia Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Critical Limb Ischemia Treatment Market Vendors
3.2. Strategies Adopted by Critical Limb Ischemia Treatment Market Vendors

4. Critical Limb Ischemia Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Critical Limb Ischemia Treatment Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape

5. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Medication
5.3.1.1. Antiplatelet Drugs
5.3.1.2. Antihypertensive Agents
5.3.1.3. Lipid-lowering Agents
5.3.1.4. Antithrombotic Agents
5.3.1.5. Others
5.3.2. Devices
5.3.2.1. Embolic Protection Devices
5.3.2.2. Peripheral Dilatation System
5.3.2.2.1. Balloon Dilators
5.3.2.2.2. Vascular Stents

6. North America Critical Limb Ischemia Treatment Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
6.3. Critical Limb Ischemia Treatment Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)

7. UK and European Union Critical Limb Ischemia Treatment Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3. Critical Limb Ischemia Treatment Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)

8. Asia Pacific Critical Limb Ischemia Treatment Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3. Critical Limb Ischemia Treatment Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)

9. Latin America Critical Limb Ischemia Treatment Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3. Critical Limb Ischemia Treatment Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)

10. Middle East and Africa Critical Limb Ischemia Treatment Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3. Critical Limb Ischemia Treatment Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Critical Limb Ischemia Treatment Market: By Treatment, 2024-2034, USD (Million)

11. Company Profile
11.1. Boston Scientific Corporation (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. Cesca Therapeutics Inc.
11.3. Abbott Laboratories
11.4. Pluristem Therapeutics Inc.
11.5. Rexgenero Ltd
11.6. LimFlow SA
11.7. Micro Medical Solutions
11.8. Cardiovascular Systems, Inc.